Brain Targeting of Quetiapine Fumarate via Intranasal Delivery of Loaded Lipospheres : Fabrication, In-Vitro Evaluation, Optimization, and In-Vivo Assessment
A liposphere system for intranasal delivery of quetiapine fumarate (QTF) was created to assess the potential for enhanced drug delivery. We investigated the effects of particle size, entrapment effectiveness, poly dispersibility index, and pluronic incorporation percentage on these variables. The optimal formula was examined using a TEM, and investigations into DSC, XRD, and FTIR were made. Optimized liposphere formulation in vitro dissolution investigation with a mean diameter of 294.4 ± 18.2 nm revealed about 80% drug release in 6 h. The intranasal injection of QTF-loaded lipospheres showed a shorter Tmax compared to that of intranasal and oral suspension, per the findings of an in vivo tissue distribution investigation in Wistar mice. Lipospheres were able to achieve higher drug transport efficiency (DTE %) and direct nose-to-brain drug transfer (DTP %). A potentially effective method for delivering QTF to specific brain regions is the liposphere system.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Pharmaceuticals (Basel, Switzerland) - 15(2022), 9 vom: 30. Aug. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zaki, Randa Mohammed [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Brain targeting |
|---|
| Anmerkungen: |
Date Revised 28.09.2022 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/ph15091083 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346616743 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346616743 | ||
| 003 | DE-627 | ||
| 005 | 20231226031901.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ph15091083 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1155.xml |
| 035 | |a (DE-627)NLM346616743 | ||
| 035 | |a (NLM)36145303 | ||
| 035 | |a (PII)1083 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zaki, Randa Mohammed |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Brain Targeting of Quetiapine Fumarate via Intranasal Delivery of Loaded Lipospheres |b Fabrication, In-Vitro Evaluation, Optimization, and In-Vivo Assessment |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.09.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a A liposphere system for intranasal delivery of quetiapine fumarate (QTF) was created to assess the potential for enhanced drug delivery. We investigated the effects of particle size, entrapment effectiveness, poly dispersibility index, and pluronic incorporation percentage on these variables. The optimal formula was examined using a TEM, and investigations into DSC, XRD, and FTIR were made. Optimized liposphere formulation in vitro dissolution investigation with a mean diameter of 294.4 ± 18.2 nm revealed about 80% drug release in 6 h. The intranasal injection of QTF-loaded lipospheres showed a shorter Tmax compared to that of intranasal and oral suspension, per the findings of an in vivo tissue distribution investigation in Wistar mice. Lipospheres were able to achieve higher drug transport efficiency (DTE %) and direct nose-to-brain drug transfer (DTP %). A potentially effective method for delivering QTF to specific brain regions is the liposphere system | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a DTE% | |
| 650 | 4 | |a brain targeting | |
| 650 | 4 | |a intranasal | |
| 650 | 4 | |a lipospheres | |
| 650 | 4 | |a quetiapine fumarate | |
| 700 | 1 | |a Aldawsari, Mohammed F |e verfasserin |4 aut | |
| 700 | 1 | |a Alossaimi, Manal A |e verfasserin |4 aut | |
| 700 | 1 | |a Alzaid, Shaikah F |e verfasserin |4 aut | |
| 700 | 1 | |a Devanathadesikan Seshadri, Vidya |e verfasserin |4 aut | |
| 700 | 1 | |a Almurshedi, Alanood S |e verfasserin |4 aut | |
| 700 | 1 | |a Aldosari, Basmah Nasser |e verfasserin |4 aut | |
| 700 | 1 | |a Yusif, Rehab Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Sayed, Ossama M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmaceuticals (Basel, Switzerland) |d 2009 |g 15(2022), 9 vom: 30. Aug. |w (DE-627)NLM199619514 |x 1424-8247 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2022 |g number:9 |g day:30 |g month:08 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/ph15091083 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2022 |e 9 |b 30 |c 08 | ||